Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07709000
PHASE2

A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

Sponsor: Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes. The goals of this trial are to learn about: * The safety of MK-1045 and if participants tolerate it. Tolerate means participants will receive trial treatment unless they need to stop treatment due to health problems. * The number of participants who respond. Respond means the number of cancer cells goes down or signs of cancer go away.

Official title: A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK-1045 in Participants With Hematologic Malignancies

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-08-21

Completion Date

2033-11-16

Last Updated

2026-07-16

Healthy Volunteers

No

Interventions

BIOLOGICAL

MK-1045

Intravenous (IV) infusion

DRUG

Acetaminophen (or similar antipyretic)

Oral administration as a premedication

DRUG

Diphenhydramine (or similar antihistamine)

Per approved product label as a premedication

DRUG

Dexamethasone

IV administration as a premedication

BIOLOGICAL

Tocilizumab

IV administration as a rescue medication

BIOLOGICAL

Tocilizumab biosimilar

IV administration as a rescue medication

BIOLOGICAL

Siltuximab

IV administration as a rescue medication